1. Efficacy and safety of a recombinant factor IX (Bax326)1 in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open‐label, uncontrolled, multicentre, phase III study. (3rd April 2014) Authors: Windyga, J.; Lissitchkov, T.; Stasyshyn, O.; Mamonov, V.; Ghandehari, H.; Chapman, M.; Fritsch, S.; Wong, W.‐Y.; Pavlova, B. G.; Abbuehl, B. E. Journal: Haemophilia Issue: Volume 20:Number 5(2014:Sep.) Page Start: 651 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of a recombinant factor IX (Bax326)1 in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open‐label, uncontrolled, multicentre, phase III study. (3rd April 2014) Authors: Windyga, J.; Lissitchkov, T.; Stasyshyn, O.; Mamonov, V.; Ghandehari, H.; Chapman, M.; Fritsch, S.; Wong, W.‐Y.; Pavlova, B. G.; Abbuehl, B. E. Journal: Haemophilia Issue: Volume 20:Number 5(2014:Sep.) Page Start: 651 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Head‐to‐head comparison of the pharmacokinetic profiles of a high‐purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B. (7th May 2013) Authors: Lissitchkov, T.; Matysiak, M.; Zavilska, K.; Laguna, P.; Gercheva, L.; Antonov, A.; Moret, A.; Caunedo, P.; Aznar, J. A.; Woodward, M. K.; Páez, A. Journal: Haemophilia Issue: Volume 19:Number 5(2013:Sep.) Page Start: 674 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in previously treated patients with severe haemophilia A. Issue 4 (31st May 2018) Authors: Dargaud, Y.; Negrier, C.; Rusen, L.; Windyga, J.; Georgiev, P.; Bichler, J.; Solomon, C.; Knaub, S.; Lissitchkov, T.; Klamroth, R. Journal: Haemophilia Issue: Volume 24:Issue 4(2018) Page Start: 619 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series. Issue 2 (15th February 2017) Authors: Iorio, A.; Barbara, A. M.; Makris, M.; Fischer, K.; Castaman, G.; Catarino, C.; Gilman, E.; Kavakli, K.; Lambert, T.; Lassila, R.; Lissitchkov, T.; Mauser‐Bunschoten, E.; Mingot‐Castellano, M. E.; Ozdemir, N.; Pabinger, I.; Parra, R.; Pasi, J.; Peerlinck, K.; Rauch, A.; Roussel‐Robert, V. Journal: Haemophilia Issue: Volume 23:Issue 2(2017) Page Start: 255 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Novel, human cell line‐derived recombinant factor VIII (human‐cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety. (28th August 2015) Authors: Lissitchkov, T.; Hampton, K.; von Depka, M.; Hay, C.; Rangarajan, S.; Tuddenham, E.; Holstein, K.; Huth‐Kühne, A.; Pabinger, I.; Knaub, S.; Bichler, J.; Oldenburg, J. Journal: Haemophilia Issue: Volume 22:Number 2(2016:Mar.) Page Start: 225 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency. (22nd January 2018) Authors: Ross, C.; Rangarajan, S.; Karimi, M.; Toogeh, G.; Apte, S.; Lissitchkov, T.; Acharya, S.; Manco‐Johnson, M. J.; Srivastava, A.; Brand, B.; Schwartz, B. A.; Knaub, S.; Peyvandi, F. Journal: Journal of thrombosis and haemostasis Issue: Volume 16:Number 2(2018) Page Start: 253 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B. (9th July 2013) Authors: Windyga, J.; Lissitchkov, T.; Stasyshyn, O.; Mamonov, V.; Rusen, L.; Lamas, J. L.; Oh, M.‐S.; Chapman, M.; Fritsch, S.; Pavlova, B. G.; Wong, W.‐Y.; Abbuehl, B. E. Journal: Haemophilia Issue: Volume 20:Number 1(2014:Jan.) Page Start: 15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A. Issue 5 (27th April 2017) Authors: Lissitchkov, T.; Rusen, L.; Georgiev, P.; Windyga, J.; Klamroth, R.; Gercheva, L.; Nemes, L.; Tiede, A.; Bichler, J.; Knaub, S.; Belyanskaya, L.; Walter, O.; Pasi, K. J. Journal: Haemophilia Issue: Volume 23:Issue 5(2017) Page Start: 697 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Prophylaxis vs. on‐demand treatment with Nuwiq® (Human‐cl rhFVIII) in adults with severe haemophilia A. (19th November 2015) Authors: Tiede, A.; Oldenburg, J.; Lissitchkov, T.; Knaub, S.; Bichler, J.; Manco‐Johnson, M. J. Journal: Haemophilia Issue: Volume 22:Number 3(2016:May) Page Start: 374 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗